Veeva Systems Inc
NYSE:VEEV
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
209.39
306.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
VEEV
stock under the Base Case scenario is
138.58
USD.
Compared to the current market price of 224.18 USD,
Veeva Systems Inc
is
Overvalued by 38%.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Veeva Systems Inc.
Fundamental Analysis
VEEV Profitability Score
Profitability Due Diligence
Score
VEEV Solvency Score
Solvency Due Diligence
Score
Select up to 3 indicators:
Select up to 3 indicators:
Heavier dependence on large pharmaceutical customers may stifle growth if key clients renegotiate contracts or reduce IT spending, potentially causing sharp revenue swings given Veeva’s concentrated client roster.
Veeva’s strategic push to penetrate non–life sciences verticals (such as consumer goods and chemicals) could be met with low adoption rates if industry-specific trust and compliance demands prove too challenging or expensive to fulfill.
Regulatory shifts and increased competition in clinical trial software—especially from established data vendors—could threaten Veeva’s margins, forcing deeper investments in R&D or price concessions to remain competitive.
Dominance in cloud-based solutions tailored for life sciences, coupled with high switching costs, positions Veeva to maintain robust renewal rates and pricing power in its core market.
Expanding the suite of products—especially the Veeva Vault platform—beyond CRM creates a larger revenue base, diversifies risk, and cements the brand’s reputation for end-to-end pharmaceutical software solutions.
Its subscription-oriented model and tight integration with regulatory-compliance processes drive consistent recurring revenue, supporting strong free cash flow that can be reinvested in new product development and potential acquisitions.
Revenue & Expenses Breakdown
Veeva Systems Inc
Balance Sheet Decomposition
Veeva Systems Inc
Veeva Systems Inc
Free Cash Flow Analysis
Veeva Systems Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Veeva Systems Inc
Wall St
Price Targets
VEEV Price Targets Summary
Veeva Systems Inc
According to Wall Street analysts, the average 1-year price target for
VEEV
is 317.82 USD
with a low forecast of 224.22 USD and a high forecast of 399 USD.
Dividends
Current shareholder yield for
VEEV is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
VEEV
stock under the Base Case scenario is
138.58
USD.
Compared to the current market price of 224.18 USD,
Veeva Systems Inc
is
Overvalued by 38%.